ANALYSIS OF BLOOD PRESSURE, SERUM HCY AND MTHFR C677T GENE POLYMORPHISM IN H HYPERTENSION

Abstract

Objective: To investigate the relationship between blood pressure and serum homocysteine (Hcy) level and C677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) in H hypertension. Methods: The clinical data of 423 hypertensive patients admitted to our hospital from October 2021 to October 2022 were retrospectively selected and divided into group H (176 cases) and non-H group (247 cases) according to whether H hypertension was hypertension or not. Compared non-H hypertension and H hypertension MTHFR C677T genotypes, blood pressure and serum Hcy levels of patients with different MTHFR C677T genotypes, and blood pressure and serum Hcy levels before and after folic acid treatment in patients with different MTHFR C677T genotypes. Results: The proportion of CC and CT patients with grade 3 hypertension was 15.52% and 36.21%, respectively, lower than 28.34% and 50.61% of non-H group, and the proportion of TT patients was 48.28%, higher than 21.05%, 32.08% and 30.77% of non-H, grade 1 and 2 hypertension (P <0.05). Serum Hcy levels in TT patients were higher than CC and CT patients; CT Hcy levels were higher than CC patients; Hcy levels in non-H TT patients were higher than CC patients; and CC, CT, and TT patients were higher than non-H patients (P <0.05).systolic pressure（SBP）、 Compared with pre-treatment, SBP, diastolic blood pressure (DBP) and serum Hcy levels were decreased after 12 weeks of treatment, but SBP and serum Hcy levels were higher in TT patients than in CC and CT patients (P <0.05). Conclusion The BP level and the distribution of SBP and serum Hcy levels are closely related to MTHFR C677T gene polymorphism. Folic acid treatment helps to reduce the SBP and serum Hcy levels, but the SBP and serum Hcy levels are still high in TT patients.